There is no compulsion under the Pharmaceutical Benefits Scheme to prescribe the maximum quantity of a drug as a pharmaceutical benefit if the medical practitioner considers a lesser quantity is sufficient for the patient's requirements (unless the maximum quantity is marked with a double dagger in the Schedule of Pharmaceutical Benefits). In fact, the Pharmaceutical Benefits Advisory Committee would prefer practitioners to prescribe the quantity that is needed rather than the maximum allowable quantity.
If a practitioner prescribes less than the maximum quantity, where the maximum quantity coincides with the standard pack, the pharmacist is compensated for dispensing the 'broken quantity' according to the 'Wastage Factor Table' (in 'Section1-Explanatory Notes' of the Schedule of Pharmaceutical Benefits). For example, if half the listed maximum quantity is prescribed (as in the case of 56 bismuth subcitrate tablets from a pack of 112), the payment to the pharmacist is 62% rather than 50% (ignoring the dispensing fee). There is thus a wastage factor of 12% built in, in this case.
In relation to acyclovir tablets 200 mg, the maximum quantity for
initial treatment of moderate to severe genital herpes is 50 tablets,
not 90 tablets, which may be dispensed from a pack of 90 tablets or two packs of 25 tablets. The pharmacist's remuneration in this case is based on supply from two packs of 25 tablets, and 'broken quantity' pricing will not apply.